

## Curriculum Vitae

<b>Name</b>	<b>Hyewon Ryu</b>	
<b>Current Position &amp; Affiliation</b>	<b>Assistant Professor, Chungnam National University College of Medicine</b>	
<b>Country</b>	<b>Republic of Korea</b>	

### Educational Background

- 2014.3. -2020.2. **Ph.D.** in Department of Internal Medicine,  
Graduate School of Chungnam National University,  
Daejeon, Korea
- 2011.3. - 2013.2. **M.S.** in Department of Internal Medicine,  
Graduate School of Chungnam National University,  
Daejeon, Korea
- 2002.3. - 2008.2. **M.D.** in College of Medicine,  
Chungnam National University,  
Daejeon, Korea

### Professional Experience

- 2020.3- Present **Assistant Professor**,  
Department of Internal Medicine,  
Chungnam National University College of Medicine,  
Daejeon, Korea
- 2016.3 – 2020.2 **Clinical Assistant Professor**,  
Department of Internal Medicine,  
Chungnam National University Hospital,  
Daejeon, Korea
- 2015.3. - 2016.2. **Clinical Fellow**,  
Division of Oncology, Department of Internal Medicine,  
Asan medical center,  
Seoul, Korea

- 2014.3. - 2015.2. **Clinical Fellow**,  
Division of Hematology/Oncology,  
Department of Internal Medicine,  
Chungnam National University Hospital,  
Daejeon, Korea
- 2010.3. - 2014.2. **Residency** in Department of Internal medicine,  
Chungnam National University Hospital
- 2008.3. - 2009.2. **Internship** in Samsung Medical Center,  
Seoul, Korea

### Professional Organizations

Member of KSMO, ESMO, EACR, ASCO, AACR

### Main Scientific Publications

\* **First Author**

1. Kim N, **Ryu H**, Kim S, Joo M, Jeon HJ, Lee MW, Song IC, Kim MN, Kim JM, Lee HJ. CXCR7 promotes migration and invasion in head and neck squamous cell carcinoma by upregulating TGF- $\beta$ 1/Smad2/3 signaling. *Sci Rep*. 2019 Dec 2;9(1):18100.
2. **Ryu H**, Baek SW, Moon JY, Jo IS, Kim N, Lee HJ. C-C motif chemokine receptors in gastric cancer. *Mol Clin Oncol*. 2018 Jan;8(1):3-8.
3. **Ryu H**, Song IC, Choi YS, Yun HJ, Jo DY, Kim JM, Ko YB, Lee HJ. ERCC1 expression status predicts the response and survival of patients with metastatic or recurrent cervical cancer treated via platinum-based chemotherapy. *Medicine (Baltimore)*. 2017 Dec;96(51):e9402
4. **Ryu H**, Lee HJ. Nivolumab and Ipilimumab in Advanced Melanoma. *N Engl J Med*. 2017 Dec 21;377(25):2503.
5. **Ryu H**, Choi YS, Song IC, Yun HJ, Jo DY, Kim S, Lee HJ. Long-term treatment of residual or recurrent low-grade endometrial stromal sarcoma with aromatase inhibitors: A report of two cases and a review of the literature. *Oncol Lett*. 2015 Nov;10(5):3310-3314.

6. **Ryu H**, Park B, Moon JY, Lee MW, Choi YS, Song IC, Jo DY. Gangrenous Cryoglobulinemic Vasculitis in a Patient with Multiple Myeloma. Korean J Med. 2013 Dec;85(6):634-638. Korean.
7. **Ryu H**, Lee C, Jo DY. Solitary pulmonary plasmacytoma. Blood Res. 2013 Sep;48(3):170.
8. **Ryu H**, Lee HJ. Beau's Lines of the Fingernails. Am J Med Sci. 2014 Mar 24.

\* **Contributing Author**

1. Lee MW, Yeon SH, Seo WH, **Ryu H**, Lee HJ, Yun HJ, Jo DY, Song IC. A comparison of post-transplantation cyclophosphamide versus antithymocyte-globulin in patients with hematological malignancies undergoing HLA-matched unrelated donor transplantation. Medicine (Baltimore). 2020 Aug 21;99(34):e21571.
2. Chae H, Jeong H, Cheon J, Chon HJ, **Ryu H**, Kim IH, Kang MJ, Jeong JH, Ryoo BY, Kim KP, Yoo C. Efficacy and safety of second-line nab-paclitaxel plus gemcitabine after progression on FOLFIRINOX for unresectable or metastatic pancreatic ductal adenocarcinoma: multicenter retrospective analysis. Ther Adv Med Oncol. 2020 May 27;12:1758835920923424.
3. Lee MW, **Ryu H**, Choi YS, Song IC, Lee HJ, Yun HJ, Sun BJ, Jeong JO, Jo DY. Pulmonary hypertension in patients with Philadelphia-negative myeloproliferative neoplasms: a single-center retrospective analysis of 225 patients. Blood Res. 2020 Jun 30;55(2):77-84.
4. Kang E, Keam B, Lee NR, Kang JH, Kim YJ, Shim HJ, Jung KH, Koh SJ, **Ryu H**, Lee J, Choo J, Yoo SH, Yun YH. Impact of family caregivers' awareness of the prognosis on their quality of life/depression and those of patients with advanced cancer: a prospective cohort study. Support Care Cancer. 2020 May 6.
5. Lee MW, **Ryu H**, Song IC, Yun HJ, Jo DY, Ko YB, Lee HJ. Efficacy of cisplatin combined with topotecan in patients with advanced or recurrent ovarian cancer as second- or higher-line palliative chemotherapy. Medicine (Baltimore). 2020 Apr;99(17):e19931.
6. Song IC, Lee MW, Baek SW, **Ryu H**, Choi YS, Jo DY. Helicobacter pylori testing in a population of Korean patients with pernicious anemia. Blood Res. 2020 Mar;55(1):69.

7. Kim S, Kim JE, Kim N, Joo M, Lee MW, Jeon HJ, **Ryu H**, Song IC, Song GY, Lee HJ. Decursin inhibits tumor growth, migration, and invasion in gastric cancer by down-regulating CXCR7 expression. *Am J Cancer Res*. 2019 Sep 1;9(9):2007-2018.eCollection 2019.
8. Park HY, Kim YA, Sim JA, Lee J, **Ryu H**, Lee JL, Maeng CH, Kwon JH, Kim YJ, Nam EM, Shim HJ, Song EK, Jung KH, Kang EJ, Kang JH, Yun YH. Attitudes of the General Public, Cancer Patients, Family Caregivers, and Physicians Toward Advance Care Planning: A Nationwide Survey Before the Enforcement of the Life-Sustaining Treatment Decision-Making Act. *J Pain Symptom Manage*. 2019 Apr;57(4):774-782.
9. Yun YH, Kang EK, Lee J, Choo J, **Ryu H**, Yun HM, Kang JH, Kim TY, Sim JA, Kim Y. Development and validation of the quality care questionnaire -palliative care (QCQ-PC): patient-reported assessment of quality of palliative care. *BMC Palliat Care*. 2018 Mar 5;17(1):40.
10. Baek SW, Moon JY, **Ryu H**, Choi YS, Song IC, Lee HJ, Yun HJ, Kim S, Jo DY. Chronic kidney disease in the BCR-ABL1-negative myeloproliferative neoplasm: a single-center retrospective study. *Korean J Intern Med*. 2017 Mar 17.
11. Moon JY, Baek SW, **Ryu H**, Choi YS, Song IC, Yun HJ, et al. VIP (etoposide, ifosfamide, and cisplatin) in patients with previously treated soft tissue sarcoma. *Medicine*. 2017;96(4):e5942
12. Song IC, Lee HJ, Yang YJ, Choi YS, **Ryu HW**, Lee MW, Moon JY, Jo DY, Kim S, Yun HJ. The efficacy and Safety of Platinum/Vinorelbine as More Than Second-Line Chemotherapy for Advanced Non-small Cell Lung Cancer. *Cancer Res Treat*. 2015 Oct;47(4):638-44
13. Yun HJ, **Ryu H**, Choi YS, Song IC, Jo DY, Kim S, Lee HJ. C-X-C motif receptor 7 in gastrointestinal cancer. *Oncol Lett*. 2015 Sep;10(3):1227-1232
14. Lee HJ, **Ryu H**, Choi YS, Song IC, Yun HJ, Jo DY, Kim S. Just Toxicity, or Toxicity As a Biomarker of Efficacy of Ramucirumab in Breast Cancer? *J Clin Oncol*. 2015 Aug 20;33(24):2712.
15. Kim HY, Moon JY, **Ryu H**, Choi YS, Song IC, Lee HJ, Yun HJ, Kim S, Jo DY. Bortezomib inhibits the survival and proliferation of bone marrow stromal cells. *Blood Res*. 2015 Jun;50(2):87-96.
16. Lee HJ, **Ryu H**, Choi YS, Song IC, Yun HJ, Jo DY, Kim S. Sorafenib for patients with differentiated thyroid cancer. *Lancet*. 2015 Jan 17;385(9964):228.

17. Baek SW, Lee MW, **Ryu HW**, Lee KS, Song IC, Lee HJ, Yun HJ, Kim S, Jo DY. Clinical features and outcomes of autoimmune hemolytic anemia: a retrospective analysis of 32 cases. Korean J Hematol. 2011 Jun;46(2):111-7.
18. Yang YJ, Yun GW, Song IC, Baek SW, Lee KS, **Ryu HW**, Lee MW, Lee HJ, Yun HJ, Kim S, Jo DY. Clinical implications of elevated antiphospholipid antibodies in adult patients with primary immune thrombocytopenia. Korean J Intern Med. 2011 Dec;26(4):449-54
-